Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Eur J Cancer Care (Engl) ; 25(3): 502-15, 2016 May.
Article in English | MEDLINE | ID: mdl-25828949

ABSTRACT

In this study, we aimed to determine the personal, social and economic burden and the frequency of depression, as well as in caregivers of cancer patients who are being treated with chemotherapy in Turkey. The study is designed as a cross-sectional survey study using a 5-point Likert-type response scale, and the last part of the questionnaire includes the Beck Depression Inventory. The depression rate was found to be 64% (n = 476) among all subjects (n = 968), with 91% of those with depression demonstrating signs of mild depression. In this study, a significant difference was found between the presence of depression and age (young), sex (female), educational level (high), economic status (low), financial loss during treatment, patient's lack of knowledge about his/her diagnosis, metastatic disease and short survival time. In addition, 64% of all subjects had concerns of getting cancer, and 44% of all subjects had feelings of anger/rage against other people. In a multivariate regression analysis, the patient's lack of knowledge of the diagnosis was the independent risk factor. In conclusion, depression incidence and burden rate increased among cancer caregivers, and care burden was highly associated with depression. Accordingly, approaches to reducing the psycho-social effects of cancer should focus intensively on both the patients and their caregivers in Turkey.


Subject(s)
Caregivers/psychology , Depressive Disorder/etiology , Neoplasms/psychology , Adolescent , Adult , Aged , Cancer Care Facilities , Cost of Illness , Cross-Sectional Studies , Emotions , Female , Humans , Male , Middle Aged , Neoplasms/drug therapy , Palliative Care/psychology , Pilot Projects , Socioeconomic Factors , Turkey , Young Adult
2.
J BUON ; 17(2): 291-8, 2012.
Article in English | MEDLINE | ID: mdl-22740208

ABSTRACT

PURPOSE: This study aimed at investigating the factors that are likely to affect recurrence and survival in patients with locally advanced rectal cancer. METHODS: The study included patients treated and followed- up between January 1999 and August 2009. Patient and disease data were retrieved from the patients' hospital charts. RESULTS: A total of 221 patients were evaluated. Their median age was 58 years (range 18-83); 69 (31.2%) patients had clinical stage II and 152 (68.8%) clinical stage III. Median follow-up was 40 months (range 8-136). Median disease free survival (DFS) was 77 months and median overall survival (OS) 95 months. The factors affecting local recurrence were pathological lymph node involvement (pN+), pathological T4 (pT4) tumors, and postoperative high serum level of carcinoembryonic antigen (CEA). pN (+) tumors, postoperative high serum CEA level, and perineural invasion increased the risk of both local and distant metastasis. The factors affecting mortality were pN+ tumors, pT4 tumors, poor tumor differentiation, high postoperative CEA level, age > 60 years, and no postoperative adjuvant chemotherapy (CT). The factors affecting DFS were pN+ tumors, pT4 tumors, poor tumor differentiation, postoperative high serum CEA level, perineural invasion, and surgical margin positivity. The factors affecting OS were pN+ tumors, postoperative high serum CEA level, poor tumor differentiation, perineural invasion and no adjuvant CT. CONCLUSION: Some prognostic factors are important in the assessment of prognosis of locally advanced rectal cancer.


Subject(s)
Adenocarcinoma, Mucinous/mortality , Adenocarcinoma/mortality , Biomarkers, Tumor/metabolism , Neoplasm Recurrence, Local/mortality , Rectal Neoplasms/mortality , Adenocarcinoma/metabolism , Adenocarcinoma/therapy , Adenocarcinoma, Mucinous/metabolism , Adenocarcinoma, Mucinous/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoembryonic Antigen/metabolism , Female , Follow-Up Studies , Humans , Immunoenzyme Techniques , Male , Middle Aged , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/therapy , Neoplasm Staging , Prognosis , Rectal Neoplasms/metabolism , Rectal Neoplasms/therapy , Survival Rate , Young Adult
3.
Asian Pac J Cancer Prev ; 13(11): 5593-7, 2012.
Article in English | MEDLINE | ID: mdl-23317223

ABSTRACT

PURPOSE: The aim of this study was to evaluate the effects of the group therapy on psychological symptoms and quality of life of patients with early stage breast cancer. METHODS: This study was performed on 16 breast cancer patients who completed treatments. The total group therapy program involved a weekly session of 2-3 hours, for 16 weeks. The group therapy sessions were given to women in the oncology department by a clinical psychologist and also given training sections by the different professional teams. All the required assessments for the study were performed after and before 16 week group therapy intervention. RESULTS: Initially we had taken 21 women but 16 participated in all therapy programs and submitted questionnaires. The mean age was 47.8 years. There were significant differences between before and after group therapy program. Anxiety, depression, and distress showed significant improvements. Hopelessness scale was detected at the border of significance. There was no change in sleep problems and quality of life. According to the analysis of correlation, considering the age factor and year of diagnosis, there was found no statistically significant relationship between anxiety, distress, depression, hopelessness, sleeplessness, and quality of life. CONCLUSIONS: This pilot study demonstrated that brief, predominantly group therapy is feasible for patients with breast cancer and, also it may be helpful to cope with emotional and physical distress.


Subject(s)
Adaptation, Psychological , Breast Neoplasms/psychology , Quality of Life , Stress, Psychological , Adult , Anxiety/etiology , Anxiety/prevention & control , Breast Neoplasms/therapy , Depression/etiology , Depression/prevention & control , Fatigue/etiology , Fatigue/prevention & control , Female , Follow-Up Studies , Health Status , Humans , Life Change Events , Middle Aged , Pilot Projects , Prognosis , Surveys and Questionnaires , Young Adult
4.
J BUON ; 16(3): 537-40, 2011.
Article in English | MEDLINE | ID: mdl-22006762

ABSTRACT

PURPOSE: The objective of this study was to determine possible differences in the perception of quality of life (QoL) between physicians and nurses working in an oncology clinic in Turkey. METHODS: Seventy-seven physicians and 67 nurses participated in this study. All participants provided information such as the working hours per day and the number of years working in an oncology clinic. The European Organization for Research and Treatment of Cancer (EORTC) QLQC30 questionnaire was used during face-to-face interviews by trained interviewers. RESULTS: The mean age of physicians and nurses were 32±0.8 and 29,9±0.9 years, respectively (p>0.05). Forty-four percent of physicians and all nurses were women. Fifty-three percent of physicians and 57% of nurses were single. Mean working hours per day and number of working years were similar between physicians and nurses. The physical, emotional, and cognitive function scales of physicians were better and statistically significant compared with nurses (p<0.0001, p<0.0006, and p<0.0127, respectively). Global health score was also better in physicians but without statistical significance. In physicians, a significant negative correlation with working hours and emotional, cognitive, role, and social function scales was found. A significant positive correlation with the number of working years and emotional function scale and also with age and role, emotional, cognitive, and social scales was found. Global health showed significant negative correlation with working hours, and positive correlation with age, number of working years, physical, role, emotional, cognitive, and social function scales. CONCLUSION: It is important to recognize that oncology workers, particularly nurses, have poor QoL. There are many factors adversely affecting the QoL of oncology workers in Turkey, therefore systems should be developed to provide better support and conditions for them.


Subject(s)
Medical Oncology , Nurses/psychology , Physicians/psychology , Quality of Life , Adult , Age Factors , Female , Humans , Male
5.
J BUON ; 15(3): 462-9, 2010.
Article in English | MEDLINE | ID: mdl-20941811

ABSTRACT

PURPOSE: Advanced pancreatic cancer (APC) has a poor prognosis and chemotherapy remains the primary treatment modality. Gemcitabine (GEM) and 5-fluorouracil (5-FU) are the most active drugs in the treatment of pancreatic cancer. This study evaluated the efficacy and tolerability of the combination of these agents in APC. METHODS: Forty-four patients with APC were treated with GEM and infusional 5-FU with high dose leucovorin (LV5FU2) (GEMFUFOL regimen). RESULTS: A total of 240 chemotherapy cycles were administered. The overall response rate was 27.2%, and all responses were partial. Furthermore, disease stabilization was observed in 12 patients (27.2%). Median survival time and one-year survival rate were 9 months and 36.4%, respectively. The overall grade 3 or 4 adverse events were very low and mostly hematological. CONCLUSION: GEMFUFOL is still an active regimen for the treatment of APC and has an acceptable toxicity.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Pancreatic Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Female , Fluorouracil/administration & dosage , Humans , Leucovorin/administration & dosage , Male , Middle Aged , Pancreatic Neoplasms/mortality , Gemcitabine
6.
J BUON ; 14(1): 135-8, 2009.
Article in English | MEDLINE | ID: mdl-19365885

ABSTRACT

Somatostatin and its long-acting analogues are effective in symptom control in patients with functional neuroendocrine tumors; they are also able to control tumor growth. Somatostatin analogues are safe and generally well tolerated. In some cases they may cause serious complications. Somatostatin analogues are potent inhibitors of growth hormone (GH) and glucagon secretion. They cause impairment of hepatic glucose output and delay in intestinal absorption of carbohydrates. Patients with huge tumor mass and multiple liver metastases have increased risk of tumor-induced hypoglycemia. In these patients, long-acting octreotide may trigger serious hypoglycemia. The patients whose glucose control is dependent on counter-regulatory hormones should be monitored for the possibility of hypoglycemia. Herein, we present a patient with severe and prolonged hypoglycemia after long-acting octreotide treatment.


Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Hypoglycemia/chemically induced , Neuroendocrine Tumors/drug therapy , Octreotide/adverse effects , Pancreatic Neoplasms/drug therapy , Somatostatin/adverse effects , Blood Glucose/metabolism , Delayed-Action Preparations , Dietary Carbohydrates/administration & dosage , Fatal Outcome , Female , Glucocorticoids/administration & dosage , Glucose/administration & dosage , Humans , Hypoglycemia/blood , Hypoglycemia/therapy , Immunohistochemistry , Infusions, Intravenous , Methylprednisolone/administration & dosage , Middle Aged , Neuroendocrine Tumors/diagnosis , Neuroendocrine Tumors/secondary , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/pathology , Radionuclide Imaging , Somatostatin/analogs & derivatives , Tomography, X-Ray Computed
7.
Rheumatology (Oxford) ; 45(6): 746-50, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16403826

ABSTRACT

OBJECTIVE: To prospectively monitor inflammatory activity over a prolonged period in a cohort of Turkish patients with FMF, their healthy relatives and healthy controls and to relate this to their MEFV genotypes. METHODS: 43 patients with FMF and 75 of their asymptomatic relatives underwent fortnightly assessments and venesection for measurement of CRP and SAA over 5 months. 50 unrelated healthy population matched controls were also studied. MEFV genotyping was performed on all participants and comparisons were made between the different groups. RESULTS: Paired MEFV mutations were detected in 84% of FMF patients and single mutations in 12%. Substantial acute phase reactivity was seen among the patients with FMF during attacks (median SAA 693 mg/l, CRP 115 mg/l). Between attacks there was also some inflammatory activity (median SAA 6 mg/l, CRP 4 mg/l). Among healthy controls 16% were heterozygotes for MEFV mutations and 4% had two mutations. As expected there was a substantial carrier rate among healthy relatives with mutations detected in almost 92%. Asymptomatic MEFV heterozygotes had elevated acute phase proteins compared to wild type subjects. CONCLUSION: Substantial sub-clinical inflammation occurs widely and over prolonged periods in patients with FMF, indicating that the relatively infrequent clinically overt attacks represent the 'tip of the iceberg' in this disorder. Both basal and peak acute phase protein concentrations were greater in MEFV heterozygotes than in wild-type controls, regardless of mutation demonstrating a 'pro-inflammatory' phenotype among FMF carriers. Upregulation of the acute phase response among carriers of FMF may augment their innate host response and contribute to better resistance to infection.


Subject(s)
Cytoskeletal Proteins/genetics , Familial Mediterranean Fever/genetics , Heterozygote , Mutation , Acute-Phase Reaction/blood , Acute-Phase Reaction/etiology , Acute-Phase Reaction/genetics , Biomarkers/blood , C-Reactive Protein/metabolism , Familial Mediterranean Fever/blood , Familial Mediterranean Fever/complications , Genotype , Humans , Prospective Studies , Pyrin , Serum Amyloid A Protein/metabolism
8.
Clin Exp Rheumatol ; 22(4 Suppl 34): S34-6, 2004.
Article in English | MEDLINE | ID: mdl-15515781

ABSTRACT

OBJECTIVE: Familial Mediterranean Fever (FMF) is a hereditary disease characterized by recurrent inflammatory attacks. A subclinical inflammation may persist in periods between the attacks and heterozygotes may have higher than normal levels of acute phase proteins. We investigated the levels of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) in FMF patients and their obligatory carrier relatives. METHODS: Serum levels of IL-6 and sIL-6R were measured during acute attacks (n = 18) and in attack-free FMF patients (n = 26), obligatory carriers of FMF (n = 17) and normal controls (n = 11). RESULTS: The median levels of IL-6 were significantly higher (45.71 pg/ mL, p = 0.001) during acute attacks of FMF only, and were normal (0.01 pg/ mL) in the other groups studied. There was no statistically significant difference in the median sIL-6R values between any of the groups (p = 0.22). CONCLUSION: IL-6 was extremely elevated during FMF attacks but could not detect hypothetical "subclinical" inflammation during attack-free intervals or in the heterozygote relatives of patients. Serum levels of sIL-6R were comparable in all four groups.


Subject(s)
Familial Mediterranean Fever , Genetic Predisposition to Disease , Heterozygote , Interleukin-6/blood , Nuclear Family , Receptors, Interleukin-6/blood , Adolescent , Adult , Enzyme-Linked Immunosorbent Assay , Familial Mediterranean Fever/genetics , Familial Mediterranean Fever/immunology , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...